Aflibercept Plus Folfiri in Asian Patients with Pretreated Metastatic Colorectal Cancer: A Randomized Phase III Study
Jin Li(Shanghai Cancer Institute), Lin Shen(Peking University), Shukui Qin(81th Hospital of PLA), Hongming Pan(Sir Run Run Shaw Hospital), Akihito Tsuji(Kagawa University Hospital), Feng Bi(Tianjin University of Traditional Chinese Medicine), Kun‐Huei Yeh(National Taiwan University Hospital), E. Magherini(Sanofi (France)), Dongmei Shi(Weifang University), Yuxian Bai(Harbin Medical University), Brigette Ma(Chinese University of Hong Kong), Tianshu Liu(Sun Yat-sen University), Jianming Xu(Chinese PLA General Hospital), Rui‐Hua Xu(Sun Yat-sen University), Vivian Wei(University of Southern California), Robert Lim(Ontario Institute for Cancer Research), Suzhan Zhang(Zhejiang Cancer Hospital), Nanfeng Fan(Fujian Medical University), Yi Ba(Tianjin Medical University Cancer Institute and Hospital)
Cited by 26
Related Papers
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group
|Journal of Clinical Oncology|2007|3.9k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k